-0.0459  (-51.01%)
Volume (24h): 36.14M Day Range: 0.0900 - 0.1950
Market Cap: 11.98M 52W Range: 0.0900 - 5.46
May-28-20 03:14PM WeWork Board Factions Head for Clash Over New DirectorsBloomberg
06:45AM WeWork Board Factions Head for Clash Over New DirectorsBloomberg
May-26-20 04:42PM Akorn, Inc. -- Moody's downgrades Akorn's PDR to D-PD following Chapter 11 filingMoody's
May-22-20 05:37PM Akorn Seeks Bankruptcy After Failed Takeover, FDA WarningsBloomberg
May-21-20 04:21PM Akorn Files Chapter 11 After Failure to Be AcquiredTheStreet.com
02:45PM Akorn Seeks Bankruptcy After Failed Takeover, FDA WarningsBloomberg
May-21-20 02:42PM Generic-Drug Maker Akorn Files Chapter 11TheStreet.com
12:01PM The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For AquestiveBenzinga
May-21-20 11:56AM Akorn Plummets 27% In Pre-Market On Bankruptcy FilingSmarterAnalyst
04:36AM Akorn Files for Bankruptcy After Failed Takeover, FDA WarningsBloomberg
May-21-20 03:52AM Akorn to Use Voluntary Chapter 11 Process to Position Business for Long-Term SuccessPR Newswire
12:12AM Forescout sues Advent to complete $1.9 billion mergerReuters
May-11-20 09:14PM Akorn Provides First Quarter 2020 ResultsGlobeNewswire
Apr-27-20 10:17PM Enphase Energy and Paylocity Set to Join S&P MidCap 400; Core Laboratories and Meredith to Join S&P SmallCap 600PR Newswire
Apr-07-20 06:08PM WeWork Directors Sue SoftBank Over Decision to Abandon DealBloomberg
03:24PM WeWork Directors Sue SoftBank Over Decision to Abandon DealBloomberg
Apr-02-20 07:59PM Bed Bath sues 1-800-Flowers for trying to renege on deal over COVID-19Reuters
Apr-01-20 10:20AM Akorn Provides Update on Sale ProcessPR Newswire
Feb-29-20 12:20PM US$4.00: That's What Analysts Think Akorn, Inc. Is Worth After Its Latest ResultsSimply Wall St.
Feb-26-20 09:58PM Akorn Provides Fourth Quarter and Full Year 2019 ResultsGlobeNewswire
Feb-19-20 02:55PM Akorn (AKRX) to Report Q4 Earnings: What's in the Cards?Zacks
Feb-12-20 10:29PM Akorn Announces New Extension of Standstill with Lenders and Agrees to Pursue a Sale of its BusinessPR Newswire
Feb-10-20 12:00PM Akorn Continues Negotiations with LendersPR Newswire
Jan-31-20 12:12PM How Many Akorn, Inc. (NASDAQ:AKRX) Shares Did Insiders Buy, In The Last Year?Simply Wall St.
Jan-14-20 05:41PM Akorn, Inc. -- Moody's announces completion of a periodic review of ratings of Akorn, Inc.Moody's
Dec-19-19 02:26PM Akorn Enters Oversold TerritoryZacks
Dec-18-19 07:52PM Akorn's stock extends plunge toward record low after disclosing it was exploring a bankruptcyMarketWatch
Dec-16-19 12:51PM Akorn Announces Extension of Standstill AgreementGlobeNewswire
Dec-11-19 06:54PM Is Akorn, Inc. (AKRX) Going To Burn These Hedge Funds ?Insider Monkey
Dec-02-19 01:00PM Easy Come, Easy Go: How Akorn (NASDAQ:AKRX) Shareholders Got Unlucky And Saw 90% Of Their Cash EvaporateSimply Wall St.
Nov-28-19 02:00PM Akorn (AKRX) Moves to Strong Buy: Rationale Behind the UpgradeZacks
Nov-26-19 01:36PM Generic Drugmakers Gain as Price-Fixing Probe Nears an EndZacks
Nov-19-19 09:54PM Teva, Bausch Could Be Next to File for BankruptcyGuruFocus.com
Nov-12-19 01:27PM The Zacks Analyst Blog Highlights: Forterra, Barrett Business, Chuy's, Akorn and QuanexZacks
Nov-11-19 12:03PM 5 Small-Cap Stocks Outpacing the Broader Market in 2019Zacks
Nov-07-19 01:22PM New Strong Buy Stocks for November 7thZacks
Nov-06-19 12:00AM Akorn to Present at the Credit Suisse Healthcare ConferenceGlobeNewswire
Nov-02-19 09:22AM Edited Transcript of AKRX earnings conference call or presentation 31-Oct-19 2:00pm GMTThomson Reuters StreetEvents
Oct-31-19 12:35PM Akorn (AKRX) Q3 Earnings and Revenues Top EstimatesZacks
11:00AM Akorn Provides Preliminary Third Quarter 2019 ResultsGlobeNewswire
Oct-24-19 02:32PM Will Akorn (AKRX) Report Negative Earnings Next Week? What You Should KnowZacks
Oct-17-19 01:00PM All You Need to Know About Akorn (AKRX) Rating Upgrade to BuyZacks
Oct-15-19 11:50AM The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J EarningsBenzinga
Oct-14-19 08:25PM Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05%GlobeNewswire
05:05PM Akorn to Report Third Quarter 2019 Financial Results and Host Conference CallGlobeNewswire
Sep-29-19 12:36PM Should You Be Concerned About Akorn, Inc.'s (NASDAQ:AKRX) Historical Volatility?Simply Wall St.
Aug-26-19 05:35PM Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15%GlobeNewswire
Aug-14-19 07:30PM Is Akorn (NASDAQ:AKRX) A Risky Investment?Simply Wall St.
Aug-08-19 02:30AM Edited Transcript of AKRX earnings conference call or presentation 1-Aug-19 1:00pm GMTThomson Reuters StreetEvents
Aug-02-19 11:24AM Akorn (AKRX) Q2 2019 Earnings Call TranscriptMotley Fool
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)